• 1
    Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011; 7:297306.
  • 2
    Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 2012; 11:203206.
  • 3
    Danoff SK, Casciola-Rosen L. The lung as a possible target for the immune reaction in myositis. Arthritis Res Ther 2011; 13:230.
  • 4
    Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2000; 12:501508.
  • 5
    Cheng OZ, Palaniyar N. NET balancing: a problem in inflammatory lung diseases. Front Immunol 2013; 4:1.
  • 6
    Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 2013; 5:178ra40.
  • 7
    Keshari RS, Jyoti A, Dubey M et al. Cytokines induced neutrophil extracellular traps formation: implication for the inflammatory disease condition. PLOS ONE 2012; 7:e48111.
  • 8
    Downey DG, Bell SC, Elborn JS. Neutrophils in cystic fibrosis. Thorax 2009; 64:8188.
  • 9
    Hakkim A, Furnrohr BG, Amann K et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010; 107:98139818.
  • 10
    Villanueva E, Yalavarthi S, Berthier CC et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011; 187:538552.
  • 11
    Leffler J, Martin M, Gullstrand B et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012; 188:35223531.
  • 12
    Kessenbrock K, Krumbholz M, Schonermarck U et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15:623625.
  • 13
    Manzenreiter R, Kienberger F, Marcos V et al. Ultrastructural characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy. J Cyst Fibros 2012; 11:8492.
  • 14
    Thomas GM, Carbo C, Curtis BR et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood 2012; 119:63356343.
  • 15
    Caudrillier A, Kessenbrock K, Gilliss BM et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 2012; 122:26612671.
  • 16
    Brinkmann V, Reichard U, Goosmann C et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303:15321535.
  • 17
    Fuchs TA, Abed U, Goosmann C et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007; 176:231241.
  • 18
    Liu CL, Tangsombatvisit S, Rosenberg JM et al. Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Res Ther 2012; 14:R25.
  • 19
    Saffarzadeh M, Juenemann C, Queisser MA et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLOS ONE 2012; 7:e32366.
  • 20
    Xu J, Zhang X, Pelayo R et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15:13181321.
  • 21
    Garcia-Romo GS, Caielli S, Vega B et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011; 3:73ra20.
  • 22
    Lande R, Ganguly D, Facchinetti V et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011; 3:73ra19.
  • 23
    Bosch X. Systemic lupus erythematosus and the neutrophil. N Engl J Med 2011; 365:758760.
  • 24
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344347.
  • 25
    Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292:403407.
  • 26
    Rider LG, Werth VP, Huber AM et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 2011; 63 (Suppl 11):S118157.
  • 27
    Macanovic M, Lachmann PJ. Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 1997; 108:220226.
  • 28
    Margraf S, Lögters T, Reipen J, Altrichter J, Scholz M, Windolf J. Neutrophil-derived circulating free DNA (cf-DNA/NETS): a potential prognostic marker for posttraumatic development of inflammatory second hit and sepsis. Shock 2008; 30:352358.